✦ LIBER ✦

Addition of rituximab to a CEOP regimen improved the outcome in the treatment of non-germinal center immunophenotype diffuse large B cell lymphoma cells with high Bcl-2 expression

✍ Scribed by Li, Yan; Yimamu, Maimaitili; Wang, Xiaomin; Zhang, Xiaoyan; Mao, Min; Fu, Ling; Aisimitula, Aihemaitijiang; Nie, Yuling; Huang, Qin

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High levels of topoisomerase IIα protein

✍ Pentheroudakis, George; Goussia, Anna; Voulgaris, Evangelos; Nikolaidis, Konstan 📂 Article 📅 2010 🏛 Informa plc 🌐 English ⚖ 391 KB

Diffuse large B-cell lymphomas with germ

✍ Bai, Maria; Skyrlas, Angelos; Agnantis, Niki John; Kamina, Sevasti; Tsanou, Elen 📂 Article 📅 2004 🏛 Nature Publishing Group 🌐 English ⚖ 191 KB

Serum levels of inflammatory cytokines a

✍ Lars M. Pedersen; Gitte W. Jürgensen; Hans E. Johnsen 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

Addition of Rituximab to Either BEAC or

✍ C.B. Williams; A. Loknath-Kumar; C.L. Divine; O.A. Aljitawi; S. Abhyankar; J.P. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 48 KB